Losartan products are about to be withdrawn from the market

Domestic pharmaceutical company A's 7 billion worth of products annually are considering withdrawing from the market

Excluding Hanmi and Oregon, the market share is less than 4%

With the recovery of Losartan with excessively detected impurities, pharmaceutical companies are considering strategies after recovery measures are completed.

 

Many pharmaceutical companies that did not have a very high market share in the Losartan market are reportedly considering gradually withdrawing from the market after the recovery is completed.

 

It is predicted that the pace of market reorganization will accelerate after the recovery measures are completed.

 

According to the pharmaceutical industry on the 20th, a large Korean pharmaceutical company A is discussing ways to stop selling the product line after the recovery of Losartan is completed.

 

Company A has five Losartan items, and some or all of these products are subject to collection.

 

According to UBIST, a pharmaceutical market research firm, the amount of outpatient prescriptions for company A's five Losartan items last year was more than 7 billion won.

 

It is confirmed that more than 5 billion won was prescribed cumulatively by the third quarter of this year.

 

The pharmaceutical industry interprets the reason why Company A is considering withdrawing the market as to resolve uncertainties.

 

Since NDMA impurities were first discovered in Valsartan in 2018, the pharmaceutical industry has struggled with the impurity crisis every year.

 

In particular, since all impurity incidents occurred in unexpected situations, it was difficult for companies as sales suspension and recovery were repeated after detecting impurities.

 

Moreover, in the case of Company A, it is considered the background of considering withdrawal from the market since it has various ARB drugs such as Telmisartan, Candesartan, Valsartan and and Irbesartan.

 

An official from Company A said, "Nothing has been accurately decided yet.

 

Losartan's prescription performance is not bad, but other ARB-based drugs are larger in terms of the total amount of prescription," he said.

 

The pharmaceutical industry predicts that pharmaceutical companies, including Company A, will withdraw from the market after the recovery of the Losartan hypertension treatment is completed.

 

As of last year, the amount of outpatient prescriptions in the hypertension treatment market, including Losartan, was 320.8 billion won, with two companies, Hanmi and Organon accounting for more than half (53.9%).

 

Hanmi's five types of Losartan recorded 122.4 billion won in prescriptions last year, accounting for 38.1% of the market share.

 

Organon accounts for 15.8%.

 

It was followed by 3.9% per Chong Kun Dang, 3.0% of SK Chemicals, 2.9% of Samik, 2.4% of Kyung Dong, 2.2% of HK inno.N, and 2.0% of Daewoong Bio.

 

In addition, 91 companies are competing for the remaining 27.5%.

 

Most pharmaceutical companies' annual prescriptions are less than 500 million won.

 

The MFDS announced on the 7th that all or some manufacturing number products of 295 items from 98 companies that were detected or feared to exceed the daily intake allowance will be voluntarily recovered.

 

The pharmaceutical industry is in the process of recovering the product.